Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:43:20.488Z.
Calculation as of: 2026-10-06T19:43:20.488Z.
Quote observation: 2026-10-06T19:33:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 426cd0b806ab2bb4e1acb1d630c97f0b27e7b6ad30a760f07fb4e7b3f4328ff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Soligenix, Inc.
Market Cap
$5.33M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Soligenix, Inc. (SNGX) | $5.33M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.31M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.28M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.23M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.17M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.14M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.06M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.17M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.61M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
